...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical Medicine Research >Efficacy and Safety of Alogliptin in Elderly Patients With Type 2 Diabetes Mellitus
【24h】

Efficacy and Safety of Alogliptin in Elderly Patients With Type 2 Diabetes Mellitus

机译：Alogliptin在老年患者2型糖尿病患者中的疗效和安全性

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In Japan, with increasing age of the population, diabetic patients often become in need of hemodialysis due to diabetic nephropathy, and thus there is a demand for development of diabetic treatments that take into account renal effects in the elderly. No previous studies of alogliptin had focused on Japanese elderly subjects; we therefore assessed the effects of alogliptin in elderly individuals using available data. Laboratory data were compiled for 1 year at intervals of 3 months following the start of alogliptin treatment. The subjects were divided into three groups by age: 65 years (n = 110), 65 - 74 years (n = 87), and ≥ 75 years (n = 93). Laboratory values in comparison with baseline were compared within groups at various time points, and changes from baseline were compared among the different groups. Hemoglobin A1c (HbA1c) levels decreased significantly from baseline values in all groups at and after month 3: the change at month 12 was -0.74±1.45% for the age group 65, -0.47±1.02% for the age group 65 - 74, and -0.42±1.11% for the age group ≥ 75. The 12-month change in estimated glomerular filtration rate (eGFR) was -6.5 ± 12.0 for the age group 65, -2.0 ± 8.4 for the age group 65 - 74, and -1.5 ± 10.0 for the age group ≥ 75; the reduction in the age group 65 was significant, whereas the reduction in the age groups ≥ 65 was not. Alogliptin significantly lowers HbA1c levels in the elderly and can be used without posing any safety issues, including renal effects, thus contributing to safe blood glucose control in clinical practice.
机译：在日本，随着年龄较大的人口，糖尿病患者由于糖尿病肾病而常被血液透析，因此需要对老年人造成肾脏效应的糖尿病治疗的需求。没有先前对Alogliptin的研究专注于日本老年人;因此，我们使用可用数据评估了Alogliptin在老年人的影响。在Alogliptin治疗开始后3个月的间隔编制了实验室数据。将受试者按年龄分为三组：<65岁（n = 110），65-74岁（n = 87），≥75岁（n = 93）。与基线相比的实验室值在各个时间点的组内比较，并且在不同的组中比较了基线的变化。血红蛋白A1C（HBA1C）水平在第3个和之后的所有群体中的基线值下降显着下降：年龄组12月12日的变化为-0.74±1.45％，年龄组65 - 74年龄组≥75的-0.42±1.11％。年龄组的估计肾小球过滤率（EGFR）的12个月变化为-6.5±12.0，年龄组65 - 74的年龄组<65,74.4年龄组≥75的-1.5±10.0;年龄组<65的减少是显着的，而年龄组的还原≥65则不是。 Alogliptin显着降低了老年人的HBA1C水平，并且可以在没有造成任何安全问题的情况下使用，包括肾脏效应，从而有助于临床实践中的安全血糖控制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号